Fresenius SE & Co. KGaA (FRE) – Investment Analysts’ Weekly Ratings Changes

Fresenius SE & Co. KGaA (FRA: FRE) recently received a number of ratings updates from brokerages and research firms:

  • 7/29/2022 –
  • 7/25/2022 – Fresenius SE & Co. KGaA was given a new €30.00 ($30.93) price target on by analysts at Jefferies Financial Group Inc..
  • 7/22/2022 – Fresenius SE & Co. KGaA was given a new €52.50 ($54.12) price target on by analysts at Barclays PLC.
  • 7/18/2022 – Fresenius SE & Co. KGaA was given a new €33.30 ($34.33) price target on by analysts at JPMorgan Chase & Co..
  • 6/27/2022 – Fresenius SE & Co. KGaA was given a new €30.00 ($30.93) price target on by analysts at Jefferies Financial Group Inc..
  • 6/23/2022 – Fresenius SE & Co. KGaA was given a new €30.00 ($30.93) price target on by analysts at UBS Group AG.
  • 6/21/2022 – Fresenius SE & Co. KGaA was given a new €52.50 ($54.12) price target on by analysts at Barclays PLC.

Fresenius SE & Co. KGaA Price Performance

FRA:FRE opened at €24.80 ($25.57) on Tuesday. Fresenius SE & Co. KGaA has a 52-week low of €60.16 ($62.02) and a 52-week high of €80.00 ($82.47). The stock has a fifty day moving average of €29.12 and a 200 day moving average of €32.26.

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.